Table 4. Front-line therapy and response rates in patients with acute or lymphomatous subtypes.
| Therapy | Number | Overall Response Rate (%) |
|---|---|---|
| Chemotherapy Only | 23 | 6 CR, 1 PR (30.4%) |
| EPOCH | 11 | 4 CR |
| CHOP | 7 | 2 CR, 1 PR |
| CVP | 1 | 0 |
| Hyper CVAD | 4 | 0 |
| Chemotherapy with antiviral | 16 | 3 CR, 3 PR (37.5%) |
| EPOCH + Bortezomib + Raltegravir | 5 | 1 CR, 2 PR |
| EPOCH + Lamivudine | 1 | 0 |
| EPOCH + Lamivudine / AZT | 8 | 2 CR, 1 PR |
| CHOP + AZT | 1 | 0 |
| Hyper CVAD + AZT | 1 | 0 |
| Other | 2 | 0 CR, 0 PR (0%) |
| IFN + AZT | 2 | 0 |
EPOCH: etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; CVP: cyclophosphamide, vincristine, prednisone; Hyper CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; IFN: interferon alpha; AZT: zidovudine; CR: complete response; PR: partial response.
(n=41).